PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study
Part of paid clinical trials in Galveston, Texas.
- Sponsor
- University of Utah
- Study ID
- NCT06945484
- Status
- Recruiting
Conditions
- NSCLC Stage II
- NSCLC, Stage III
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Precision Exercise Regimen for Cancer Care (PERCC) — OTHERPERCC has exercise modes including basic transfer and calisthenics mobility, aerobic, and resistance exercises, and will be performed in various postures (supine, sitting, standing, and walking) with variable challenges (level walking, bending, inclines, steps, and squatting). Each participant will complete one supervised, home-based exercise training session per week, delivered through telehealth, that will focus on the resistance exercise prescription. Other unsupervised exercise training sessions will focus on the aerobic exercise prescription and will be completed individually
Study Details
This study is designed to evaluate whether a precision exercise regimen is feasible to implement within cancer populations, specifically stage II-III primary lung cancer patients receiving multimodal therapy, and delivered through telehealth.
Key Dates
- Start date
- Nov 21, 2025
- Status verified
- Jul 2025
- Primary completion
- Jan 31, 2027
- Completion
- Dec 31, 2030
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Precision Exercise Regimen for Cancer Care (PERCC)Participants will engage in PERCC starting at least two weeks prior to receiving their first neoadjuvant treatment for lung cancer and continuing until two months after receiving surgical treatment.
Primary Outcome Measure
Feasibility - Recruitment and Retention [ Time Frame: up to two months post-surgery ]
Central Contacts
- Thomas Varghese, MD, MS, MBA, FACS801-581-5311
- Cornelia Ulrich, MS, PhD801-213-5716
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Texas Medical Branch at Galveston | Galveston | Texas | 77555 | |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | Cornelia Ulrich, MS, PhD |
Find similar trials in Galveston, TX
Related Studies
- Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLCPHASE3 · Recruiting · Maximilian Diehn · Stanford, California
- Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC PatientsRecruiting · Jun Zhang, MD, PhD · Kansas City, Kansas
- A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung DiseasePHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey